April 18, 2023 - TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the presentation of two posters at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.
The first poster indicates a PD-L1/CLEVER-1 IHC staining ratio may be used to predict bexmarilimab response, as responding patients have a low PD-L1 and high CLEVER-1 staining, as well as low inflammatory cytokine (IFNγ, TNFα, IL-6) levels as reported previously. This finding means they are often refractory to checkpoint inhibitors and other T cell activating agents.
The second poster indicates that bexmarilimab can induce activation and secondary Ig rearrangements in mature B-cells. B-cell diversity and activation is considered important for cancer immune recognition.